Overview

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
SOTIO a.s.
Treatments:
Pembrolizumab